CTI BioPharma Corp. logo
CTI BioPharma Corp. CTIC

Quarterly report 2023-Q1
added 05-15-2023

report update icon

CTI BioPharma Corp. Financial Statements 2011-2026 | CTIC

Annual Financial Statements CTI BioPharma Corp.

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

551 M 171 M 236 M 70.1 M 65.6 M 110 M 130 M 237 M 327 M 379 M 84.9 M 187 M

Shares

115 M 90.1 M 71.1 M 58 M 56.1 M 36.4 M 27.9 M 18.8 M 14.9 M 11.4 M 5.81 M 3.43 M

Historical Prices

4.8 1.9 3.25 0.98 1.02 4.02 4.21 5.4 23.4 38.5 13.5 64.5

Net Income

-93 M -97.9 M -52.5 M -40 M -29.3 M -40.7 M -52 M -119 M -93.4 M -42.7 M -101 M -62.4 M

Revenue

53.9 M - 4.2 K 3.34 M 26.3 M 25.1 M 57.4 M 16.1 M 60.1 M 34.7 M - -

Cost of Revenue

3.51 M - - - 879 K 364 K - - - - - -

Gross Profit

- - 4.2 K - 25.4 M 24.8 M 56 M 14.2 M 59.2 M 34.5 M - -

Operating Income

-79.8 M -95.3 M -47.8 M -40.7 M -32.9 M -39.5 M -49.2 M -117 M -86.2 M -41.5 M -101 M -62.2 M

Interest Expense

13.1 M 2.42 M 828 K 1 M 1.21 M 1.87 M 2.61 M 2.1 M 1.95 M 1.03 M 56 K 870 K

EBITDA

-77.8 M -94.8 M -47.2 M -39.4 M -31.6 M -38.8 M -48.3 M -116 M -85.1 M -39.8 M -98.2 M -70.8 M

Operating Expenses

- - 47.8 M 43.3 M 57.6 M 64.3 M 105 M 131 M 145 M 75.9 M 101 M 73.2 M

General and Administrative Expenses

84.8 M 56.2 M 17.6 M 19.2 M 21.2 M 31.4 M 45.3 M 54 M 56.2 M 42.3 M 38.2 M 38.3 M

All numbers in USD currency

Quarterly Income Statement CTI BioPharma Corp.

2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

132 M 131 M 122 M 109 M 99.8 M 99.8 M 93.8 M 92.3 M 76.4 M 75.9 M 73.7 M 73.7 M 62.5 M 58 M 58 M 58 M 58 M 58 M 58 M 57.9 M 50.3 M 43 M 42.9 M 31.7 M 28 M 28.2 M 28 M 28 M 27.8 M 28 M 176 M 175 M 174 M 177 M 145 M 144 M 142 M 146 M 111 M 108 K 107 M 110 M 52.9 M 42.5 M 40.8 M 40.6 M 37 M 165 M 203 M

Net Income

-13.4 M - -15.7 M -22.7 M -37.2 M - -24.2 M -19.7 M -17.3 M - -11.3 M -14 M -12.2 M - -10 M -11 M -10.8 M - -14.8 M -11.3 M -4.02 M -14.3 M -12 M 5.4 M -19.8 M -6.37 M -29.2 M -19.8 M 3.31 M -25.6 M -32.6 M -32.6 M -28.6 M -41.6 M 4.6 M -27.4 M -29 M 10.2 M -15.5 M -18 M -19.4 M -18.6 M -15.2 M -50.1 M -17.4 M -8.97 M -16.7 M -17 M -19.7 M

Revenue

24.1 M - 18.2 M 12.3 M 2.3 M - - - - - - - - - 2.29 M 416 K 640 K - 723 K 613 K 10.5 M 462 K 1.7 M 22.2 M 754 K 9.14 M 4.43 M 7.36 M 36.5 M 11.3 M 964 K 1.1 M 2.73 M 17.8 M 39.5 M 1.34 M 1.41 M 32.9 M 362 K 306 K 1.13 M - - - - - - - -

Cost of Revenue

1.22 M - 1.15 M 917 K 278 K - - - - - - - - - - - - - 114 K 588 K - - 69 K 78 K - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - -84 K -69 K 149 K 493 K 151 K 751 K 815 K 1.03 M 351 K -86 K 669 K 622 K 2.18 M 1.77 M 946 K 1.12 M 487 K 349 K 270 K 1.07 M - - - - - - - -

Operating Income

-9.23 M - -12.2 M -18.9 M -35.1 M - -23.4 M -19.5 M -17.1 M - -11 M -10 M -11.9 M - -9.71 M -11 M -10.5 M - -14.8 M -14 M -4.34 M - -11.8 M 5.27 M -19.3 M - -28.7 M -19.1 M 4.13 M - -32 M -31 M -27.5 M - 7.47 M -26.7 M -27.7 M - -15.5 M -17.9 M -18.5 M -18.8 M -15.1 M -49.4 M -18.1 M -9.91 M -15.3 M -16.9 M -20.1 M

Interest Expense

4.18 M - 3.56 M 3.76 M 2.06 M - 653 K 167 K 187 K - 115 K 137 K 167 K - 240 K 269 K 294 K - 308 K 297 K 288 K - 457 K 488 K 534 K - 634 K 677 K 714 K - 1.29 M 597 K 494 K - 472 K 467 K 464 K - 316 K 316 K 48 K - 43 K 3 K 5 K - 161 K 222 K 389 K

EBITDA

-8.71 M - -10.8 M -18 M -34.8 M - -23 M -19.2 M -16.9 M - -10.6 M -9.73 M -11.8 M - -9.3 M -10.7 M -10.4 M - -14.3 M -13.7 M -4.18 M - -11.2 M 5.65 M -19.1 M - -28 M -18.6 M 4.36 M - -31.2 M -30.5 M -27.2 M - 8.35 M -26.1 M -27.3 M - -14.3 M -17 M -18.1 M -18.8 M -13.4 M -48.3 M -17.6 M -9.91 M -13.5 M -15.9 M -19.6 M

General and Administrative Expenses

21.9 M - 21.5 M 21.6 M 18 M - 13.7 M 10.2 M 7.63 M - 4.05 M 3.8 M 4.47 M - 4.4 M 5.05 M 5.21 M - 5.76 M 5.49 M 5.5 M - 5.8 M 7.96 M 10.7 M - 15.2 M 9.57 M 11.3 M - 13.7 M 12.6 M 12.3 M - 12.6 M 13.8 M 16.8 M - 8.53 M 10.1 M 11.1 M - 7.76 M 11.3 M 9.93 M - 7.76 M 8.96 M 8.58 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements CTI BioPharma Corp. CTIC
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting CTI BioPharma Corp. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.37 -8.67 % $ 350 M britainBritain
Adagene Adagene
ADAG
$ 1.65 3.77 % $ 92.9 M chinaChina
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.4 -3.41 % $ 8.18 B australiaAustralia
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 66.18 0.38 % $ 8.85 B usaUSA
Biogen Biogen
BIIB
$ 179.22 -3.45 % $ 26.1 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
AstraZeneca PLC AstraZeneca PLC
AZN
$ 94.23 0.64 % $ 96.9 B britainBritain
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 214.43 2.72 % $ 5 B danmarkDanmark
Codiak BioSciences Codiak BioSciences
CDAK
- -55.98 % $ 2.15 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 56.12 0.63 % $ 114 B usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
- - $ 7.29 B usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Caladrius Biosciences Caladrius Biosciences
CLBS
- -16.75 % $ 25.8 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.88 0.52 % $ 908 M israelIsrael
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
BioNTech SE BioNTech SE
BNTX
$ 106.68 4.4 % $ 27.2 B germanyGermany
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 4.11 -2.61 % $ 8.94 B israelIsrael
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 11.04 0.55 % $ 727 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.7 3.03 % $ 160 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 29.26 -0.48 % $ 1.42 B usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 26.03 1.4 % $ 1.68 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 4.26 -0.12 % $ 116 M franceFrance
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 9.61 -0.36 % $ 1.55 B britainBritain